NCT04325165 is a NA clinical trial of DBS Implantation in Spinal Cord Injuries, sponsored by University Health Network, Toronto.

Who is sponsoring NCT04325165?

NCT04325165 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT04325165?

Interventions in NCT04325165: DBS Implantation.

What condition does NCT04325165 study?

NCT04325165 studies Spinal Cord Injuries, Spinal Injuries, Spinal Fractures.

Is NCT04325165 still recruiting?

NCT04325165 is currently withdrawn. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT04325165

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DBS of PPN to Improve Walking in Chronic SCI Patients

Withdrawn NA Last updated 3 November 2020

What this trial tests

NA trial testing DBS Implantation in Spinal Cord Injuries. Withdrawn.

Timeline

30 June 2015

Primary endpoint
26 November 2018

26 November 2018

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	30 June 2015
Primary completion	26 November 2018
Estimated completion	26 November 2018

Drugs / interventions tested

DBS Implantation

Conditions studied

Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
Spinal Injuries — all drugs for Spinal Injuries →
Spinal Fractures — all drugs for Spinal Fractures →

Sponsor

University Health Network, Toronto

Who can join

Adults 18 to 65, any sex, with Spinal Cord Injuries or Spinal Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spinal cord injury (SCI) is a devastating condition affecting over 1 million individuals in North America. SCI often results in severe motor impairments with few available treatments options. Recent groundbreaking research has demonstrated that deep brain stimulation (DBS) of the mesencephalic locomotor region (MLR) greatly improves locomotion in a rat model with incomplete SCI. The pedunculopontine nucleus (PPN - a specific nucleus within the MLR) in humans has already been established as an auxillary DBS target in Parkinson Disease (PD), to improve motor control and locomotion. DBS of other targets has also been safely used in humans with SCI for chronic pain. These findings suggest that DBS of the PPN may have potential as a therapeutic intervention in the SCI population to improve locomotion. Our goal is to conduct a pioneering study in 5 select motor-incomplete chronic SCI patients that cannot functionally ambulate to examine if bilateral DBS of the PPN improves walking

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04325165 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04325165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing